Max Zeller Soehne AG

Romanshorn, Switzerland

Max Zeller Soehne AG

Romanshorn, Switzerland
SEARCH FILTERS
Time filter
Source Type

Ruedeberg C.,University of Bern | Wiesmann U.N.,University of Bern | Brattstroem A.,Max Zeller Soehne AG | Honegger U.E.,University of Bern
Phytotherapy Research | Year: 2010

Classic synthetic antidepressant drugs, as well as St John's wort extract (SJW), directly inhibit the re-uptake of norepinephrine (NE) and/or serotonin (5-HT) into pre-synaptic axons. With chronic treatment they induce adaptive changes in a number of neurotransmitter receptors in synaptic membranes. The immediate effects of SJW Ze 117, an extract low in hyperforin content, on the specific dopamine (DA) uptake were studied in rat striatal brain slices and compared with the effects on NE and 5-HT uptake in rat cortical brain slices. Specific DA uptake was inhibited in a dose dependent manner. In contrast to the findings in synaptosomal preparations published so far, the extract showed different inhibitory potencies for the respective transporters. The potencies for the uptake inhibition of NA, DA and 5-HT were 30, 7 and 1, respectively. The results indicate that the SJW Ze 117 extract interferes in three ways with the individual uptakes of the relevant neurotransmitters that are considered to be causal in the development of depression. This observation, the concomitant and potent inhibition of DA re-uptake by SJW extract, may additionally provide a rationale for the treatment of nicotine or drug addiction with SJW. Copyright © 2009 John Wiley & Sons, Ltd.


Moser C.,Max Zeller Soehne AG | Vickers S.P.,RenaSci Ltd. | Brammer R.,RenaSci Ltd. | Cheetham S.C.,RenaSci Ltd. | Drewe J.,Max Zeller Soehne AG
Phytomedicine | Year: 2014

Introduction It was the aim of the present experiments to examine potential antidiabetic effects of the Cimicifuga racemosa extract Ze 450. Methods Ze 450 and some of its components (23-epi-26-deoxyactein, protopine and cimiracemoside C) were investigated in vitro for their effects on AMP-activated protein kinase (AMPK) compared to metformin in HepaRG cells. Ze 450 (given orally (PO) and intraperitonally (IP)), metformin (PO) and controls were given over 7 days to 68 male ob/ob mice. Glucose and insulin concentrations were measured at baseline and during an oral glucose tolerance test (OGTT). Results Ze 450 and its components activated AMPK to the same extent as metformin. In mice, Ze 450 (PO/IP) decreased significantly average daily and cumulative weight gain, average daily food and water intake, while metformin had no effect. In contrast to metformin, PO Ze 450 virtually did not change maximum glucose levels during OGTT, however, prolonged elimination. Ze 450 administered PO and IP decreased significantly post-stimulated insulin, whereas metformin did not. HOMA-IR index of insulin resistance improved significantly after IP and PO Ze 450 and slightly after metformin. In summary, the results demonstrate that Ze 450 reduced significantly body weight, plasma glucose, improved glucose metabolism and insulin sensitivity in diabetic ob/ob mice. In vitro experiments suggest that part of the effects may be related to AMPK activation. Conclusions Ze 450 may have utility in the treatment of type 2 diabetes. However, longer term studies in additional animal models or patients with disturbed glucose tolerance or diabetes may be of use to investigate this further. © 2014 Elsevier GmbH. All rights reserved.


Schellenberg R.,Institute for Health Care and Science | Zimmermann C.,Max Zeller Soehne AG | Drewe J.,Max Zeller Soehne AG | Hoexter G.,Dr. M. Koehler GmbH Pharma Biometrie Consulting | Zahner C.,Max Zeller Soehne AG
Phytomedicine | Year: 2012

Background: Preparations of Vitex agnus castus L. (VAC) have been shown to be effective to treat irregular menstrual cycles, cyclical mastalgia and symptoms of the premenstrual syndrome (PMS). However, the dose-effect relationship for the treatment of PMS has not yet been established. This study aimed to investigate the clinical effects of three different doses of the VAC extract Ze 440 in comparison to placebo in patients suffering from PMS. Methods: In a multicenter, double-blind, placebo-controlled, parallel-group study, 162 female patients with PMS (18-45 years) were randomized to either placebo or different doses of Ze 440 (8, 20 and 30 mg) over three menstrual cycles. PMS symptoms' severity was assessed by patients using visual analog scales (VAS) for the symptoms irritability, mood alteration, anger, headache, bloating and breast fullness. Results: Each of the treatments was well tolerated. Improvement in the total symptom score (TSS) in the 20 mg group was significantly higher than in the placebo and 8 mg treatment group. The higher dose of 30 mg, on the other hand, did not significantly decrease symptom severity compared to the 20 mg treatment, providing a rational for the usage of 20 mg. Corresponding results were observed with the single PMS symptom scores. Conclusion: This study demonstrated that the VAC extract Ze 440 was effective in relieving symptoms of PMS, when applied in a dose of 20 mg. Therefore, for patients suffering from PMS, 20 mg Ze 440 should be the preferred daily dose. © 2012 Elsevier GmbH.


Patent
Max Zeller Soehne Ag | Date: 2013-07-03

The present invention relates to the novel use of an extract from a Cimicifuga species, preferably Cimicifuga racemosa (also termed Actaea racemosa L; black cohosh). In particular, the invention is directed to an extract from Cimicifuga sp., preferably Cimicifuga racemosa, for use in the therapeutic or prophylactic treatment of diabetes, preferably diabetes mellitus type 2, the use of such extracts for preparing a medicament, corresponding pharmaceutical compositions comprising the extract as well as a method for the therapeutic or prophylactic treatment of diabetes, preferably by oral administration of the extract or pharmaceutical composition.


PubMed | Max Zeller Soehne AG and RenaSci Ltd.
Type: Journal Article | Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology | Year: 2014

It was the aim of the present experiments to examine potential antidiabetic effects of the Cimicifuga racemosa extract Ze 450.Ze 450 and some of its components (23-epi-26-deoxyactein, protopine and cimiracemoside C) were investigated in vitro for their effects on AMP-activated protein kinase (AMPK) compared to metformin in HepaRG cells. Ze 450 (given orally (PO) and intraperitonally (IP)), metformin (PO) and controls were given over 7 days to 68 male ob/ob mice. Glucose and insulin concentrations were measured at baseline and during an oral glucose tolerance test (OGTT).Ze 450 and its components activated AMPK to the same extent as metformin. In mice, Ze 450 (PO/IP) decreased significantly average daily and cumulative weight gain, average daily food and water intake, while metformin had no effect. In contrast to metformin, PO Ze 450 virtually did not change maximum glucose levels during OGTT, however, prolonged elimination. Ze 450 administered PO and IP decreased significantly post-stimulated insulin, whereas metformin did not. HOMA-IR index of insulin resistance improved significantly after IP and PO Ze 450 and slightly after metformin. In summary, the results demonstrate that Ze 450 reduced significantly body weight, plasma glucose, improved glucose metabolism and insulin sensitivity in diabetic ob/ob mice. In vitro experiments suggest that part of the effects may be related to AMPK activation.Ze 450 may have utility in the treatment of type 2 diabetes. However, longer term studies in additional animal models or patients with disturbed glucose tolerance or diabetes may be of use to investigate this further.

Loading Max Zeller Soehne AG collaborators
Loading Max Zeller Soehne AG collaborators